Background: Hyponatremia (HYPO) is a known predictor of mortality in pts hospitalized for worsening heart failure. However, it is not known whether ITYPO is only a marker of disease severity or whether improving sodium levels in hyponatremic patients would lead to improved outcomes. We studied the relationship between changes in serum sodium during hospitalization and mortality in hyponatremic patients admitted for decompensated heart failure (HI:) in a post-hoc analysis of the ACTIV in CHF trial. Methods: The ACTIV in CIIF trial randomized 319 pts with systolic dysfunction hospitalized for worsening HI: to receive placebo or 30, 60, or 90 mg tolvaptan, a novel vasopressin V2 receptor antagonist. Cox proportional hazards regression-analysis was used to explore the relationship between ITYPO (Na+<136 mEq/L) at baseline and improvements >2 mEq/L in serum sodium by hospital discharge, and mortality within sixty days. Results: Mild to moderate HYPO was observed in 69 patients (21.6%), with median (IR) levels of 133 (131, 134) mEq/L at baseline. After adjustment for other covariates, HYPO was a highly statistically significant predictor of mortality at 60 days post hospital discharge (p<0.005). At hospital discharge, 45 out of 69 pts (65.2%) had improvements in serum sodium levels >2 mEq/L. These pts had a median (IR) baseline sodium of 133 (131, 134) mEq/L, as compared with 133 (132, 135) mEq/L in those who did not improve by hospital discharge. Pts with a serum sodium improvement at discharge had a mortality rate of 15.6% at 60 days post discharge, as compared with a 30.4% mortality rate in those showing no improvement (p=0.0842, log-rank). After adjustment for other covariates, change in serum sodium within the hospitalization period was a statistically significant predictor of mortality at 60 days post hospital discharge (p<0.0269).
Background: The EPHESUS trial demonstrated that patients with acute myocardial infarction (AMI) complicated by heart failure (HF) and left ventricular systolic dysfunction (LVSD) experienced significant reductions in mortality and morbidity with eplerenone treatment started at a mean of 7.3 days post-AMI and used with standard therapy during a mean 16-month follow-up period. Given the adverse impact of hypertension, diabetes, and severe LVSD (LVEF_< 30%) on post-AMI outcomes, and the increased risk for mortality and morbidity during the first 30 days following an AMI in patients with HF and LVSD, the current analysis at 30 days post-randomization was performed to explore the early onset of eplerenone benefit in these high-risk subgroups. Methods: In EPHESUS, patients with post-AMI HF and LVSD (ejection fraction _<40%) on standard therapies were randomized 3-14 days after the index AMI to eplerenone (25 mg titrated to 50 mg QD at 1 month; n=3319) or placebo (n=3313). The assessment of the treatment effects at 30 days post-randomization was performed on the intention-to-treat patients in high-risk subgroups using a Cox proportional hazards regression model with treatment group as the only factor, stratified by geographic region. The estimated 95% confidence intervals were based on the Wald test statistic. 
Conclusions:
In EPHESUS, eplerenone reduced all-cause mortality by 32%, 30%, and 43% in the hypertensive, diabetic and LVEF _<30% subgroups, respectively, within 30 days of initiation. Eplerenone also notably reduced the other end points, including CV mortality and sudden cardiac death, during this period of increased risk. These data demonstrate the early benefits of eplerenone in high-risk patients with HF post-AMI and suggest the need for early initiation and maintenance of eplerenone treatment in these patients.
354
Internal We utilized a monitor based on the novel principal of Internal Thoracic Impedance (ITI) measurement that allows recognition of small fluid changes in the lung.Device was applied in AMI patients for the diagnosis of the interstitial stage of AHF and to examine whether early initiation of treatment can prevent the alveolar stage of AHF. Patients without evidence of AHF on admission were monitored for 72 hours. ITI, respiratory rate, heart rate, lung rales and blood saturation were measured every 30 minutes. Study included 399 patients (mean age 63.14-12.8) with AMI. Of these,315 remained without AHF (group 1),63 patients developed AHF throughout monitoring (group 2), and 21 received early treatment(group 3).Lung rales was the first clinical sign to appear of all variables. ITI decrease in group 1 was 4.54-3.3% (NS) from initial value (range, 0-11.5%). All group 2 patients developed mild AHF, 80% progressed to
